drugset / Trial / NCT05201638
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
Timeline
- Start
- 2022-01-12
- Primary completion
- 2026-11
- Completion
- 2033-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vidofludimus | Small molecule | 15 mg | Oral |
| Subject | Vidofludimus | Small molecule | 30 mg | Oral |